Equillium Inc
Company Profile
Business description
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.
Contact
2223 Avenida De La Playa
Suite 105
La JollaCA92037
USAT: +1 858 240-1200
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
14
Stocks News & Analysis
stocks
SpaceX: What investors need to know about its enormous upcoming IPO
stocks
Fair value lifts for toll road operator as Aussie fuel supply steadies
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,934.50 | 14.40 | -0.16% |
| CAC 40 | 8,146.59 | 36.75 | -0.45% |
| DAX 40 | 25,003.04 | 101.66 | -0.40% |
| Dow JONES (US) | 51,078.88 | 46.42 | 0.09% |
| FTSE 100 | 10,338.95 | 70.33 | -0.68% |
| HKSE | 25,768.87 | 370.69 | 1.46% |
| NASDAQ | 27,086.81 | 114.19 | 0.42% |
| Nikkei 225 | 66,113.08 | 821.25 | -1.23% |
| NZX 50 Index | 13,189.40 | 55.15 | -0.42% |
| S&P 500 | 7,599.96 | 19.90 | 0.26% |
| S&P/ASX 200 | 8,697.90 | 8.80 | -0.10% |
| SSE Composite Index | 4,056.24 | 1.50 | -0.04% |